Viewing Study NCT06269133


Ignite Creation Date: 2025-12-25 @ 2:45 AM
Ignite Modification Date: 2025-12-26 @ 1:24 AM
Study NCT ID: NCT06269133
Status: ACTIVE_NOT_RECRUITING
Last Update Posted: 2025-08-27
First Post: 2024-02-13
Is NOT Gene Therapy: False
Has Adverse Events: False

Brief Title: Evaluation of Cemiplimab in Combination With Platinum-Doublet Chemotherapy in First-Line (1L) Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) in Adult United States (US) Patients
Sponsor: Regeneron Pharmaceuticals
Organization:

Study Modules

Identification Module Status Module Sponsor Collaborators Module Oversight Module Description Module Conditions Module Design Module Arms Interventions Module Outcomes Module Eligibility Module Contacts Locations Module